{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:32:12Z","timestamp":1782732732704,"version":"3.54.5"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ygyno.2014.10.001","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T14:52:02Z","timestamp":1413211922000},"page":"441-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group Study"],"prefix":"10.1016","volume":"135","clinical-trial-number":[{"clinical-trial-number":"nct01015118","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01225887","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6541-9580","authenticated-orcid":false,"given":"Don S.","family":"Dizon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn F.","family":"McGonigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zia","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-5887","authenticated-orcid":false,"given":"David S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-1581","authenticated-orcid":false,"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly K.","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.10.001_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2014.10.001_bb0010","first-page":"167","article-title":"Tumoral vascularity as a prognostic factor in cancer","author":"Weidner","year":"1996","journal-title":"Important Adv Oncol"},{"key":"10.1016\/j.ygyno.2014.10.001_bb0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/74651","article-title":"Mechanisms of angiogenesis and arteriogenesis","volume":"6","author":"Carmeliet","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.ygyno.2014.10.001_bb0020","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2007.01.019","article-title":"A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study","volume":"105","author":"McMeekin","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.10.001_bb0025","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1470-2045(01)00556-3","article-title":"Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications","volume":"2","author":"Toi","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2014.10.001_bb0030","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.001_bb0035","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ygyno.2012.08.020","article-title":"A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"127","author":"Coleman","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.10.001_bb0040","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1038\/sj.onc.1210529","article-title":"Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes","volume":"26","author":"Pollock","year":"2007","journal-title":"Oncogene"},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2014.10.001_bb0045","first-page":"E115","article-title":"A phase II trial of brivanib in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"22","author":"Powell","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"8 (Suppl. 1)","key":"10.1016\/j.ygyno.2014.10.001_bb0055","first-page":"7","article-title":"AGO-OVAR 12: A randomized controlled GCIG\/ENGOT-intergroup phase III trial of standard frontline chemotherapy +\/\u2212 nintedanib for advanced ovarian cancer","volume":"23","author":"Du Bois","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.10.001_bb0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.10.001_bb0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1740774512450101","article-title":"A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials","volume":"9","author":"Sill","year":"2012","journal-title":"Clin Trials Lond Engl"},{"key":"10.1016\/j.ygyno.2014.10.001_bb0070","article-title":"Strategies for molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial tumors with mutant p53","volume":"828165","author":"Meng","year":"2013","journal-title":"Obstet Gynecol Int"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581401350X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581401350X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T11:26:17Z","timestamp":1538133977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581401350X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S009082581401350X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.10.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.722006345.793527263","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group Study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}